Advanz Hits Back Over £100m+ Fines For UK Liothyronine Pricing

Firm ‘Utterly Disagrees’ With CMA And Vows To Appeal Decision

 
• By Dave Wallace

Advanz Pharma has immediately hit back at a decision announced by the UK’s competition regulator to impose fines of more than £100m over the firm’s historical pricing of liothyronine tablets.

CMA HQ London The Competition and Markets Authority - the HQ of the UK Competition & Markets Authority or CMA at 25 Cabot Square, Canary Wharf, London
The CMA announced fines of more than £100m over liothyronine pricing • Source: Alamy

More from Drug Pricing

More from Policy & Regulation